Outcome of Board Meeting

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/79 November 04, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code – 532523 Scrip Symbol – BIOCON Dear Sir/Madam, Subject: Outcome of the Board Meeting Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we wish to inform you that the Board of Directors at its meeting held today, i.e. Wednesday, November 04, 2026, inter alia, has: (i) Financial results: Approved the unaudited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standards (Ind-AS) for the quarter and half-year ended September 30, 2026. A copy of the aforesaid unaudited financial results along with the limited review report of the statutory auditors is enclosed herewith. (ii) Changes in Senior Management Personnel: (a) Noted the resignation of Dr. Mandar Shrikant Ghatnekar as the Chief Technology Officer (Senior Management Personnel) of the Company w.e.f. close of business hours of December 31, 2026. A copy of his letter of resignation is enclosed herewith. (b) Based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Mukesh Rathi as the Chief Technology Officer (Senior Management Personnel) of the Company w.e.f. January 01, 2027. The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, with reference to the aforesaid changes are given as “Annexure I”. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 11:20 A.M. and concluded at 01:10 P.M. Kindly take the above information on record and acknowledge. Thanking You. Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Encl: As above ANNEXURE I Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sl. Particulars Details 1. Name Mandar Shrikant Ghatnekar Mukesh Rathi 2. Reason for change viz. Resignation as the Chief Appointment as the Chief appointment, re-appointment, Technology Officer (Senior Technology Officer (Senior resignation, removal, death or Management Personnel) Management Personnel) otherwise 3. Date of appointment/re- With effect from close of With effect from January appointment/cessation (as business hours of December 31, 01, 2027 applicable) & term of 2026 appointment/re-appointment 4. Brief profile (in case of Not Applicable Enclosed as Annexure A appointment) 5. Disclosure of relationships Not Applicable Not Applicable between directors (in case of appointment of a director) ANNEXURE A BRIEF PROFILE - MUKESH RATHI Mukesh Rathi brings over 27 years of leadership experience across digital transformation, AI-led innovation, process excellence, and technology management. Prior to joining us, he served as Group Chief Digital Officer at Hinduja Group, where he spearheaded the Group’s enterprise-wide digital and AI strategy. Before that, he spent over a decade at Dr. Reddy’s Laboratories in senior leadership roles, including Global Chief Digital and Information Officer, driving enterprise-wide transformation, strengthening process excellence, and leveraging technology to accelerate business performance and innovation. Earlier in his career, Mukesh held leadership and consulting roles at Hewlett Packard, SAP, and Unilever, building a strong foundation in technology, business transformation, and operational excellence. Date:23rd October 2026 Biocon limited 20th KM, Hosur Road, Electronic City. Bangalore, India ~ 560100 Subject: Stepping down as Chief Technology Officer Dear Sir/Madam. This is to inform that I hereby tender my resignation as the Chief Technology Officer of Biocon limited effective from the dose of business hours on December 31, 2026 to take up opportunities outside the organisation. I express my sincere gratitude to the Board for the opportunity, trust and support extended to me during my tenure. I hereby consent to use this letter for the purpose of making disclosures. under SEBI {Listing Obligations and Disciosure Requirements) Regulations, 2015 and relevant filings with the appropriate authorities/regulators as may be required. Thanking You, Ma dar Shrikant Ghatnekar BIOCON LIMITED CIN: L24234KA1978PLC003417 Website: www.biocon.com Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE -560 100 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 (Rs. in Million, except per equity share data) 3 months ended 3 months ended 3 months ended 6 months ended 6 months ended Previous year ended SI. No. Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income Revenue from operations 6,305 6,245 5,833 12,550 11,204 23,464 Other income 907 648 1,338 1,555 1,951 3,197 Total income 7,212 6,893 7,171 14,105 13,155 26,661 2 Expenses a) Cost of materials consumed 2,995 2,619 3,207 5,614 6,087 11,424 b) Purchases of stock-in-trade 65 241 65 452 452 c) Changes in inventories of finished goods, work-in-progress and (190) 182 (784) (8) (1,327) (1,187) stock-in-trade d) Employee benefits expense 1,171 1,331 1,262 2,502 2,519 4,672 e) Finance costs 219 173 672 392 1,234 1,424 f) Depreciation and amortisation expense 382 384 338 766 671 1,373 g) Other expenses 1,437 1,440 1,378 2,877 2,744 5,848 6,014 6,194 6,314 12,208 12,380 24,006 Less: Recovery of cost from co-development partners (net) (6) (6) Total expenses 6,014 6,194 6,314 12,208 12,374 24,000 3 Profit before tax and exceptional items (1-2) 1,198 699 857 1,897 781 2,661 4 Exceptional items (net) [refer note 16] (2,151) 5 Profit before tax (3 + 4) 1,198 699 857 1,897 781 510 6 Tax expense [refer note 16] Current tax charge 253 167 32 420 43 120 Deferred tax charge 28 10 116 38 112 18 7 Profit for the period/ year (5-6) 917 522 709 1,439 626 372 8 Other comprehensive income/ (loss) A (i) Items that will not be reclassified to profit or loss (131) 98 63 (33) (27) 48 (ii) Income tax relating to items that will not be reclassified to profit or loss 20 (12) (9) 8 10 (3) B (i) Items that will be reclassified to profit or loss 67 40 (61) 107 (54) (317) (ii) Income tax relating to items that will be reclassified to profit or loss (17) (10) 16 (27) 14 80 Total other comprehensive income/ (loss), net of taxes (61) 116 9 55 (57) (192) 9 Total comprehensive income for the period/ year (7+8) 856 638 718 1,494 569 180 10 Paid-up equity share capital (Face value of Rs. 5 each) 8,148 8,148 6,685 8,148 6,685 8,105 11 Reserves i.e. Other equity 2,62,693 12 Earnings per share (Face value of Rs. 5 each) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) (a) Basic 0.56 0.32 0.55 0.88 0.49 0.27 (b) Diluted 0.56 0.32 0.55 0.88 0.48 0.27 See accompanying notes to the financial results BIOCON LIMITED CIN: L24234KA1978PLC003417 Website: www.biocon.com Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE· S60100 STANDALONE BALANCE SHEET (Rs. in Million) As at As at SeQtember 30, 2026 March 31, 2026 (Unaudited) (Audited) A ASSETS 1 Non-current assets (a) Property, plant and equipment 12,104 12,809 (b) Capital work-in-progress 5,633 5,232 (c) Investmen [Showing first 8,000 characters — download PDF for full document]